PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with Pfizer Inc. in order to accelerate the discovery of small molecules of medicines, developing a platform technology based on generative chemistry.

PostEra's machine learning technology aims to accelerate the drug discovery process by developing new molecular structures with optimized potency and drug-like properties. PostEra's methods take chemical synthesis into account, as well as incorporate design hypotheses for medicinal chemicals.

Through collaboration, companies will leverage Pfizer's extensive data and experience with PostEra's technological resources to promote the science of generative chemistry and produce state-of-the-art, scalable models that could potentially be implemented in internal drug discovery efforts. -clinics.

PostEra will receive an advance payment and may receive additional payments as the project progresses. PostEra will also retain ownership rights to all algorithms developed during the collaboration.

"PostEra is pleased to work with Pfizer to address some of the key pain points in pre-clinical drug discovery," said Aaron Morris , CEO of PostEra. "As a team, we are proud to be part of this collaboration and we will be leveraging PostEra's many advances in machine learning to help Pfizer accelerate progress towards new therapies."

"We believe that our investments in machine learning technologies can help us accelerate the discovery of preclinical drugs. PostEra technology complements this effort, and we are excited to see the results of the collaboration," said Charlotte Allerton , Head of Design of Medicine from Pfizer.